Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomized trials.
15 Oct, 2021 | 02:07h | UTC
Commentary on Twitter
https://twitter.com/NicoleKuderer/status/1423002503138795521
Open access